Photograph shows doses of Imvanex vaccine used to protect against Monkeypox virus at the Edison municipal vaccination center in Paris on July 27, 2022. AFP
The announcement comes amid growing criticism that authorities have been too slow in deploying the vaccine, potentially missing the window to contain what could soon become an entrenched infectious disease.
Nearly two weeks ago, the Food and Drug Administration said it had finished the necessary inspections at Bavarian Nordic's facility in Denmark, where the company fills vials of the vaccine.
The FDA said via Twitter on Wednesday that the certification had been finalized. The doses are already in the US ``so that they would be ready to be distributed once the manufacturing changes were approved,'' the agency said.
The US already has sent more than 310,000 doses of the two-shot Jynneos vaccine to state and local health departments. But clinics in San Francisco, New York and other major cities say they still don't have enough shots to meet demand.
The head of the US Department of Health and Human Services said Wednesday officials would announce more allocations on Thursday.
Officials at the San Francisco Department of Health welcomed the news, saying they need many thousands more vaccine doses than the 7,800 they have received to date.
``Without enough vaccine supply, we would have trouble fulfilling our basic duty of keeping our communities safe,'' the agency said in a statement.
Washington, DC, officials said Wednesday they would join their counterparts in San Francisco, New York City and other cities who have stopped offering appointments for second vaccine doses due to short supplies.
They said the single-dose strategy would allow them to ``vaccinate more people at risk and slow the spread of monkeypox in the community more quickly.''
The monkeypox virus mainly spreads through skin-on-skin contact, but it can also transmit through touching linens used by someone with the infection.
The vast majority of cases reported have been in men who have sex with men, though health officials have stressed that anyone can catch the virus.
People with monkeypox may experience fever, body aches, chills and fatigue. Many in the outbreak have developed zit-like bumps on many parts of the body.
The sluggish federal response has drawn comparisons to the initial days of the COVID-19 outbreak, but experts had pointed out that the US had one huge advantage: more than 1 million doses of vaccine in the strategic national stockpile.
But it turned out US officials had only about 2,000 doses on hand when the outbreak was first identified in May. Shipping and regulatory delays have meant only a portion of the rest were deployed.
``There's not enough doses,'' said Dr. Perry Halkitis of Rutgers University. ``I think with some quicker action on part of federal government we might not be in the situation we are now.''
The doses previously shipped came from a separate facility in Denmark that already had FDA clearance. Another 786,000 doses made at a newly opened Bavarian Nordic facility were awaiting the US certification announced Wednesday.
The FDA requires inspections of all vaccine manufacturing plants to assure safety, sterility and consistency of production.
US officials announced orders this month for 5 million more doses, though most of those are not expected to arrive until next year
Officials have recommended the shots be given to people who know or suspect they were exposed to monkeypox in the previous two weeks.
The Jynneos vaccine has never been widely used in response to an outbreak like this, and the government will track how well it's working,